English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduOnly a small percentage of older adults who are in the early stages of Alzheimer’s disease meet the eligibility criteria to receive new monoclonal antibody treatments, drugs that target amyloid-ß plaques in the brain, an early sign of Alzheimer’s disease. The new research is published in the August 16, 2023, online issue of Neurology®, the medical journal of the American Academy of Neurology. Clinical trial results for these drugs are only available in people in the early symptomatic stages of the disease, mild cognitive impairment or mild dementia due to Alzheimer’s disease.
Tag: aducanumab
Cedars-Sinai Experts Available to Explain Breaking News About Alzheimer’s Disease Advances
Experts from the Jona Goldrich Center for Alzheimer’s and Memory Disorders at Cedars-Sinai are available for interviews and to comment on research being presented at the conference.
Fixed vial sizes for controversial Alzheimer’s drug could waste $605 million in Medicare spending each year
Medicare could waste up to $605 million per year on the controversial Alzheimer’s drug aducanumab if it is eventually approved for widespread use because it is supplied in vials containing fixed doses that may not be appropriate for all patients–resulting in the trashing of large volumes of unused drug
UNLV Alzheimer’s Researcher and Expert Panel Present First-Use Recommendations For Aducanumab
A group of six leading Alzheimer’s experts has convened to make the first recommendations for the appropriate use of aducanumab (Aduhelm, Biogen/Eisai), a newly approved treatment for early Alzheimer’s disease. The recommendations will help provide clinicians with greater clarity and…
Johns Hopkins Drug Commercialization Expert Looks at Controversy over Alzheimer’s Treatment
Johns Hopkins Carey Business School Senior Lecturer Supriya Munshaw – an expert in the commercialization of early-stage technologies, especially in the life science and medical device industries – offers her insights into the FDA’s rationale for approving the Alzheimer’s drug aducanumab, the price set by Biogen, the future of FDA leadership, and other related topics, in this Q&A.
University of Maryland Medical Center neurologist available for interviews about new Alzheimer’s Disease drug
News outlets: In your coverage of the historic FDA approval of aducanumab, the first drug approved for disease modification of Alzheimer’s Disease, not just treatment of symptoms, please consider speaking with University of Maryland Medical Center neurologist Dr. Julia Biernot.…
Renowned Alzheimer’s Clinical Trials Researcher Available to Comment on June 7 FDA Approval of Aducanumab
The Food and Drug Administration on June 7 approved Aducanumab, which will carry the brand name Aduhelm, as the first new treatment for Alzheimer’s disease in nearly 20 years. Dr. Jeffrey L. Cummings, UNLV research professor and leading expert on Alzheimer’s clinical trials, calls…